Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect Get link Facebook X Pinterest Email Other Apps October 23, 2022 Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study - ScienceDirect Get link Facebook X Pinterest Email Other Apps Comments
Comments
Post a Comment